研究论文

靶向SOS1抗肿瘤候选药物的设计、合成与生物活性评价

  • 陈刚胜 ,
  • 徐畅 ,
  • 赵雅莉 ,
  • 李双辰 ,
  • 苏熠东 ,
  • 房雷 ,
  • 苟少华
展开
  • a江苏省生物药物高技术研究重点实验室 南京 211189, 中国;
    b江苏豪森药业集团有限公司 连云港 222000, 中国;
    c糖化学与生物技术教育部重点实验室(江南大学)

收稿日期: 2026-07-26

  修回日期: 2026-09-07

  网络出版日期: 2026-09-22

Development of SOS1 targeting molecules as antitumor candidates: design, synthesis, and biological activity evaluations

  • Gangsheng Chen ,
  • Chang Xu ,
  • Yali Zhao ,
  • Shuangchen Li ,
  • Yidong Su ,
  • Lei Fang ,
  • Shaohua Gou
Expand
  • aSchool of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China;
    bJiangsu Hansoh Pharmaceutical Group CO., LTD., Lianyungang 222000, China;
    cKey Laboratory of Carbohydrate Chemistry and Biotechnology (Jiangnan University), Ministry of Education

Received date: 2026-07-26

  Revised date: 2026-09-07

  Online published: 2026-09-22

Supported by

Priority Academic Program Development of Jiangsu Higher Education Institutions and the National Science and Technology Major Foundation of China.

摘要

为筛选SOS1抑制剂,本文设计并合成了18种嘧啶并[4,5-b]吡啶衍生物,同时评价其潜在抗肿瘤活性。药理实验结果表明,多数测试化合物对SOS1具有较强抑制作用,可显著抑制携带KRAS G12C突变的肿瘤细胞株。其中,化合物5a、5d、4c、4d和4f在小鼠中吸收良好。进一步试验证实,代表化合物4c在大鼠和犬中同样具有良好的吸收。同时4c体内抑瘤活性突出,毒性较小,具备进一步开展临床前成药性评价的研究价值。

本文引用格式

陈刚胜 , 徐畅 , 赵雅莉 , 李双辰 , 苏熠东 , 房雷 , 苟少华 . 靶向SOS1抗肿瘤候选药物的设计、合成与生物活性评价[J]. 有机化学, 0 : 202605028 . DOI: 10.6023/cjoc202605028

Abstract

To identify SOS1 inhibitors, eighteen pyrimido[4,5-b]pyridine derivatives were designed, synthesized and evaluated for their potential antitumor activity. Pharmacological data demonstrated that most of the tested compounds exhibited potent inhibitory activity against SOS1 and could significantly suppress the tumor cells lines harboring the KRAS G12C mutation. Among them, compounds 5a, 5d, 4c, 4d and 4f showed favorable absorption profile in mice. Subsequent assays confirmed that the representative compound 4c also possessed good absorption properties in rats and dogs. Notably, compound 4c exhibited remarkable in vivo antitumor efficacy, which warrants further preclinical pharmacokinetic, safety, and pharmacodynamic evaluations.

参考文献

[1] Liu P.; Wang Y.; Li X.Acta Pharmaceutica Sinica B 2019, 9(5), 871.
[2] Canon J.; Rex K.; Saiki A. Y.; Mohr C.; Cooke K.; Bagal D.; Gaida K.; Holt T.; Knutson C. G.; Koppada N.; Lanman B. A.; Werner J.; Rapaport A. S.; San Miguel, T.; Ortiz, R.; Osgood, T.; Sun, J.-R.; Zhu, X.; McCarter, J. D.; Volak, L. P.; Houk, B. E.; Fakih, M. G.; O’Neil, B. H.; Price, T. J.; Falchook, G. S.; Desai, J.; Kuo, J.; Govindan, R.; Hong, D. S.; Ouyang, W.; Henary, H.; Arvedson, T.; Cee, V. J.; Lipford, J. R.Nature 2019, 575(7781), 217.
[3] Sun Q.; Burke J. P.; Phan J.; Burns M. C.; Olejniczak E. T.; Waterson A. G.; Lee T.; Rossanese O. W.; Fesik S. W.Angew Chem Int Ed 2012, 51(25), 6140.
[4] Kessler D.; Bergner A.; Böttcher J.; Fischer G.; Döbel S.; Hinkel M.; Müllauer B.; Weiss-Puxbaum, A.; McConnell, D. B.Future Med. Chem. 2020, 12(21), 1911.
[5] Hillig R. C.; Sautier B.; Schroeder J.; Moosmayer D.; Hilpmann A.; Stegmann C. M.; Werbeck N. D.; Briem H.; Boemer U.; Weiske J.; Badock V.; Mastouri J.; Petersen K.; Siemeister G.; Kahmann J. D.; Wegener D.; Böhnke N.; Eis K.; Graham K.; Wortmann L.; Von Nussbaum, F.; Bader, B.Proc. Natl. Acad. Sci. U.S.A. 2019, 116(7), 2551.
[6] Liceras-Boillos, P.; Jimeno, D.; García-Navas, R.; Lorenzo-Martín, L. F.; Menacho-Marquez, M.; Segrelles, C.; Gómez, C.; Calzada, N.; Fuentes-Mateos, R.; Paramio, J. M.; Bustelo, X. R.; Baltanás, F. C.; Santos, E.Molecular and Cellular Biology 2018, 38(16), e00049.
[7] Fuentes-Calvo, I.; Martinez-Salgado, C.Front. Physiol. 2021, 12, 645044.
[8] Tanaka N.; Lin J. J.; Li C.; Ryan M. B.; Zhang J.; Kiedrowski L. A.; Michel A. G.; Syed M. U.; Fella K. A.; Sakhi M.; Baiev I.; Juric D.; Gainor J. F.; Klempner S. J.; Lennerz J. K.; Siravegna G.; Bar-Peled, L.; Hata, A. N.; Heist, R. S.; Corcoran, R. B.Cancer Discovery 2021, 11(8), 1913.
[9] Awad M. M.; Liu S.; Rybkin I. I.; Arbour K. C.; Dilly J.; Zhu V. W.; Johnson M. L.; Heist R. S.; Patil T.; Riely G. J.; Jacobson J. O.; Yang X.; Persky N. S.; Root D. E.; Lowder K. E.; Feng H.; Zhang S. S.; Haigis K. M.; Hung Y. P.; Sholl L. M.; Wolpin B. M.; Wiese J.; Christiansen J.; Lee J.; Schrock A. B.; Lim L. P.; Garg K.; Li M.; Engstrom L. D.; Waters L.; Lawson J. D.; Olson P.; Lito P.; Ou S.-H.I.; Christensen, J. G.; Jänne, P. A.; Aguirre, A.[J] .N Engl J Med 2021, 384(25), 2382.
[10] Ramharter J.; Kessler D.; Ettmayer P.; Hofmann M. H.; Gerstberger T.; Gmachl M.; Wunberg T.; Kofink C.; Sanderson M.; Arnhof H.; Bader G.; Rumpel K.; Zöphel A.; Schnitzer R.; Böttcher J.; O’Connell, J. C.; Mendes, R. L.; Richard, D.; Pototschnig, N.; Weiner, I.; Hela, W.; Hauer, K.; Haering, D.; Lamarre, L.; Wolkerstorfer, B.; Salamon, C.; Werni, P.; Munico-Martinez, S.; Meyer, R.; Kennedy, M. D.; Kraut, N.; McConnell, D. B.J. Med. Chem. 2021, 64(10), 6569.
[11] Hofmann M. H.; Gmachl M.; Ramharter J.; Savarese F.; Gerlach D.; Marszalek J. R.; Sanderson M. P.; Kessler D.; Trapani F.; Arnhof H.; Rumpel K.; Botesteanu D.-A.; Ettmayer P.; Gerstberger T.; Kofink C.; Wunberg T.; Zoephel A.; Fu S.-C.; Teh J. L.; Böttcher J.; Pototschnig N.; Schachinger F.; Schipany K.; Lieb S.; Vellano C. P.; O’Connell, J. C.; Mendes, R. L.; Moll, J.; Petronczki, M.; Heffernan, T. P.; Pearson, M.; McConnell, D. B.; Kraut, N.Cancer Discovery 2021, 11(1), 142.
[12] Xiong Y.; Li F.; Babault N.; Dong A.; Zeng H.; Wu H.; Chen X.; Arrowsmith C. H.; Brown P. J.; Liu J.; Vedadi M.; Jin J.J. Med. Chem. 2017, 60(5), 1876.
[13] Guram A. S.; Buchwald S. L.J. Am. Chem. Soc. 1994, 116(17), 7901.
[14] Katamreddy S. R.; Carpenter A. J.; Ammala C. E.; Boros E. E.; Brashear R. L.; Briscoe C. P.; Bullard S. R.; Caldwell R. D.; Conlee C. R.; Croom D. K.; Hart S. M.; Heyer D. O.; Johnson P. R.; Kashatus J. A.; Minick D. J.; Peckham G. E.; Ross S. A.; Roller S. G.; Samano V. A.; Sauls H. R.; Tadepalli S. M.; Thompson J. B.; Xu Y.; Way J. M.J. Med. Chem. 2012, 55(24), 10972.
文章导航

/

〈 〉